

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sanai Health Industry Group Company Limited**

**三愛健康產業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1889)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

After a preliminary assessment on the unaudited consolidated management accounts of the Group and other information currently available, the board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record (i) a revenue of approximately RMB175.92 million for the year ended 31 December 2022 (the “**Period**”), representing an increase of approximately 160.2% as compared with the year ended 31 December 2021; and (ii) a profit attributable to owners of the Company of approximately RMB29.22 million for the Period, representing an increase of approximately 223.6% as compared with the year ended 31 December 2021.

The Board considers that such increase during the Period was mainly attributable to the increase in both the sales of self-manufactured pharmaceutical products as well as the sales of pharmaceutical products of other non-competing pharmaceutical companies.

As the Company is still in the process of finalizing the consolidated results of the Group for the Period, the information contained in this announcement is only a preliminary assessment by the Board and may be subject to adjustments upon further review. Details of the financial information of the Group for the Period will be disclosed in the annual results announcement of the Company, which is expected to be published before the end of March 2023 in compliance with the requirements of the Listing Rules.

By Order of the Board  
**Sanai Health Industry Group Company Limited**  
**SHE Hao**  
*Executive Director*

Hong Kong, 28 March 2023

*As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.*